The company said that its Q1 revenue growth was driven in part by SARS-CoV-2 test revenues of €102.0 million, booked mainly in the US, Canada, and Europe.
The firm processed approximately 9,400 billable samples in Q1, a 62 percent increase compared to approximately 5,800 samples in Q1 of 2020.
News items for the in vitro diagnostics industry for the week of May 10, 2021.
The company posted a first quarter net profit of $7.9 million, or $.26 per share, compared with a year-ago net loss of $1.1 million, or $.05 per share.
The firm had a net loss of $13.3 million, or $.58 per share, in Q1 2021 compared to a net loss of $1.7 million, or $.76 per share, a year ago.
The company also said the number of tests performed in the quarter declined 3 percent from the fourth quarter of 2020.
The BD Onclarity test can now be used with samples collected at home on the firm's BD Viper and BD Cor molecular diagnostic systems.
OpGen said it is awaiting a clearance decision for its Unyvero pneumonia cartridge in China, where it is currently under review and pending approval.
The partnership will introduce additional types of test reference materials to users of the platform, including the Seraseq FFPE Tumor Fusion RNA Reference Material v4.
The company's Q1 revenues rose to $1.5 million from $1.2 million as it performed 3,775 OVA1 tests, up 3 percent from 3,654 tests in Q1 2020.